Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy

Despite the tremendous advances in the treatment of multiple myeloma, mortality remains significant, highlighting the need for new effective strategies. In recent years, daratumumab, a novel human monoclonal antibody, binding CD38, has dramatically improved outcomes either as monotherapy or in combi...

Full description

Saved in:
Bibliographic Details
Published inCancer management and research Vol. 12; pp. 7891 - 7903
Main Authors Dima, Danai, Dower, Joshua, Comenzo, Raymond L, Varga, Cindy
Format Journal Article
LanguageEnglish
Published New Zealand Taylor & Francis Ltd 01.01.2020
Dove
Dove Medical Press
Subjects
Anemia
Antibodies
Apoptosis
Bone marrow
Clinical trials
Cytotoxicity
daratumumab
FDA approval
Glycoproteins
Immunotherapy
Monoclonal antibodies
Multiple myeloma
newly diagnosed multiple myeloma
Pharmacokinetics
Plasma
relapsed/refractory multiple myeloma
Review
Targeted cancer therapy
United States > US
daratumumab
relapsed/refractory multiple myeloma
newly diagnosed multiple myeloma
Online AccessGet full text

Cover

More Information
Summary:Despite the tremendous advances in the treatment of multiple myeloma, mortality remains significant, highlighting the need for new effective strategies. In recent years, daratumumab, a novel human monoclonal antibody, binding CD38, has dramatically improved outcomes either as monotherapy or in combination with traditional regimens. Originally approved for relapsed/refractory multiple myeloma, this breakthrough medication is now being used as frontline therapy in patients with newly diagnosed multiple myeloma regardless of transplant eligibility, with trials showing promising results. Its tolerable side-effect profile and enhanced efficacy have led to its widespread incorporation into the management of multiple myeloma and further exploration about its use in other entities such as smoldering myeloma, MGUS, MGRS and amyloidosis. This comprehensive review will discuss daratumumab's mechanism of action and safety profile, as well as research which has defined its current approved indications, and ongoing clinical investigation that will define its future.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1179-1322
1179-1322
DOI:10.2147/CMAR.S212526